Molecular epidemiology and drug-resistance of tuberculosis in Luodian revealed by whole genome sequencing

Infect Genet Evol. 2021 Sep:93:104979. doi: 10.1016/j.meegid.2021.104979. Epub 2021 Jun 24.

Abstract

In this study, we aimed to investigate the molecular epidemiology and drug-resistance profiles of tuberculosis (TB) in Luodian, an area with highest TB incidence and limited healthcare resources in Guizhou, China. The passive case finding strategy was used to identify suspected pulmonary TB with symptoms, and individuals with positive Mycobacterium tuberculosis (MTB) culture were enrolled from May 22, 2018 to April 21, 2019. All the 107 cases except three came from nine towns, including 55.1% from Longping and Bianyang. The phylogeny tree showed that 53.3% of strains were Lineage 2 (Beijing genotype), while 46.7% were Lineage 4 (Euro-American genotype). Among Lineage 2 strains, 66.7% were of "modern" Beijing type. Seven clusters with genomic distance within 12 SNPs were identified. The clusters included 14 strains, accounting for a clustering rate of 13.1%. The distance separating the clustered cases was between 2.1 and 71.0 km (Km), with an average paired distance of 21.8 Km (interquartile range, 2.8-38.0 Km). Based on the gene mutations associated with drug-resistance, we predicted that 4.8% of strains were resistant to isoniazid, 3.7% to rifampicin, and 3.7% to streptomycin; only one strain (0.9%) had multidrug resistance (MDR). This study found low drug-resistance rates in Luodian, and the sub-lineage of the "modern" Beijing branch has recent expansion in Luodian. This work may also serve as a genomic baseline to assess the evolution and spread of MTB in Guizhou.

Keywords: Clustering rate; Drug-resistance; Modern Beijing; Tuberculosis; Whole genome sequencing.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Anti-Bacterial Agents / pharmacology*
  • China / epidemiology
  • Drug Resistance, Bacterial / genetics*
  • Female
  • Humans
  • Incidence
  • Isoniazid / pharmacology*
  • Male
  • Middle Aged
  • Molecular Epidemiology
  • Phylogeny
  • Prevalence
  • Rifampin / pharmacology*
  • Streptomycin / pharmacology*
  • Tuberculosis, Multidrug-Resistant / epidemiology*
  • Tuberculosis, Multidrug-Resistant / prevention & control
  • Tuberculosis, Pulmonary / epidemiology*
  • Tuberculosis, Pulmonary / prevention & control
  • Whole Genome Sequencing
  • Young Adult

Substances

  • Anti-Bacterial Agents
  • Isoniazid
  • Rifampin
  • Streptomycin